CN116848174A - Antiviral resin composition and molded article - Google Patents
Antiviral resin composition and molded article Download PDFInfo
- Publication number
- CN116848174A CN116848174A CN202280009992.7A CN202280009992A CN116848174A CN 116848174 A CN116848174 A CN 116848174A CN 202280009992 A CN202280009992 A CN 202280009992A CN 116848174 A CN116848174 A CN 116848174A
- Authority
- CN
- China
- Prior art keywords
- antiviral
- virus
- resin composition
- parts
- block copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 54
- 239000011342 resin composition Substances 0.000 title claims abstract description 22
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 44
- 229920000570 polyether Polymers 0.000 claims abstract description 40
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 38
- 229920001400 block copolymer Polymers 0.000 claims abstract description 27
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 36
- 229920006346 thermoplastic polyester elastomer Polymers 0.000 claims description 31
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 15
- 229920000909 polytetrahydrofuran Polymers 0.000 claims description 13
- 238000007334 copolymerization reaction Methods 0.000 claims description 11
- 229920001451 polypropylene glycol Polymers 0.000 claims description 9
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 abstract description 9
- 150000004706 metal oxides Chemical class 0.000 abstract description 9
- 239000000654 additive Substances 0.000 abstract description 5
- 239000010408 film Substances 0.000 abstract description 5
- 238000001125 extrusion Methods 0.000 abstract description 4
- 239000000835 fiber Substances 0.000 abstract description 4
- 239000006260 foam Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000007924 injection Substances 0.000 abstract description 4
- 239000004745 nonwoven fabric Substances 0.000 abstract description 4
- 238000005886 esterification reaction Methods 0.000 description 36
- 241000700605 Viruses Species 0.000 description 34
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 30
- 238000006068 polycondensation reaction Methods 0.000 description 30
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 21
- 230000032050 esterification Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 15
- YHWCPXVTRSHPNY-UHFFFAOYSA-N butan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCC[O-].CCCC[O-].CCCC[O-].CCCC[O-] YHWCPXVTRSHPNY-UHFFFAOYSA-N 0.000 description 13
- 229920001971 elastomer Polymers 0.000 description 13
- 239000000806 elastomer Substances 0.000 description 13
- 239000007795 chemical reaction product Substances 0.000 description 12
- 150000002009 diols Chemical class 0.000 description 12
- 229920006345 thermoplastic polyamide Polymers 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 11
- -1 e.g. Chemical compound 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WIHMDCQAEONXND-UHFFFAOYSA-M butyl-hydroxy-oxotin Chemical compound CCCC[Sn](O)=O WIHMDCQAEONXND-UHFFFAOYSA-M 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 241001678559 COVID-19 virus Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000714201 Feline calicivirus Species 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 3
- 229940035437 1,3-propanediol Drugs 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001746 injection moulding Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- QFGCFKJIPBRJGM-UHFFFAOYSA-N 12-[(2-methylpropan-2-yl)oxy]-12-oxododecanoic acid Chemical compound CC(C)(C)OC(=O)CCCCCCCCCCC(O)=O QFGCFKJIPBRJGM-UHFFFAOYSA-N 0.000 description 2
- PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 229920003232 aliphatic polyester Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- WOZVHXUHUFLZGK-UHFFFAOYSA-N dimethyl terephthalate Chemical compound COC(=O)C1=CC=C(C(=O)OC)C=C1 WOZVHXUHUFLZGK-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical group CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PXGZQGDTEZPERC-UHFFFAOYSA-N 1,4-cyclohexanedicarboxylic acid Chemical compound OC(=O)C1CCC(C(O)=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-N 0.000 description 1
- ALVZNPYWJMLXKV-UHFFFAOYSA-N 1,9-Nonanediol Chemical compound OCCCCCCCCCO ALVZNPYWJMLXKV-UHFFFAOYSA-N 0.000 description 1
- BUZMJVBOGDBMGI-UHFFFAOYSA-N 1-phenylpropylbenzene Chemical compound C=1C=CC=CC=1C(CC)C1=CC=CC=C1 BUZMJVBOGDBMGI-UHFFFAOYSA-N 0.000 description 1
- OJRJDENLRJHEJO-UHFFFAOYSA-N 2,4-diethylpentane-1,5-diol Chemical compound CCC(CO)CC(CC)CO OJRJDENLRJHEJO-UHFFFAOYSA-N 0.000 description 1
- CPWZXPYBVCANNT-UHFFFAOYSA-N 2-(4-cyclohexylphenoxy)ethanol Chemical compound C1=CC(OCCO)=CC=C1C1CCCCC1 CPWZXPYBVCANNT-UHFFFAOYSA-N 0.000 description 1
- YIFFAEJYCUTZAO-UHFFFAOYSA-N 2-(4-propylphenoxy)ethanol Chemical compound CCCC1=CC=C(OCCO)C=C1 YIFFAEJYCUTZAO-UHFFFAOYSA-N 0.000 description 1
- UTNSTOOXQPHXJQ-UHFFFAOYSA-N 2-[4-[4-(2-hydroxyethoxy)phenyl]sulfonylphenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1S(=O)(=O)C1=CC=C(OCCO)C=C1 UTNSTOOXQPHXJQ-UHFFFAOYSA-N 0.000 description 1
- SDQROPCSKIYYAV-UHFFFAOYSA-N 2-methyloctane-1,8-diol Chemical compound OCC(C)CCCCCCO SDQROPCSKIYYAV-UHFFFAOYSA-N 0.000 description 1
- XCSGHNKDXGYELG-UHFFFAOYSA-N 2-phenoxyethoxybenzene Chemical compound C=1C=CC=CC=1OCCOC1=CC=CC=C1 XCSGHNKDXGYELG-UHFFFAOYSA-N 0.000 description 1
- SXFJDZNJHVPHPH-UHFFFAOYSA-N 3-methylpentane-1,5-diol Chemical compound OCCC(C)CCO SXFJDZNJHVPHPH-UHFFFAOYSA-N 0.000 description 1
- CARJPEPCULYFFP-UHFFFAOYSA-N 5-Sulfo-1,3-benzenedicarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=CC(S(O)(=O)=O)=C1 CARJPEPCULYFFP-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229930182764 Polyoxin Natural products 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ORLQHILJRHBSAY-UHFFFAOYSA-N [1-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1(CO)CCCCC1 ORLQHILJRHBSAY-UHFFFAOYSA-N 0.000 description 1
- XMUZQOKACOLCSS-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=CC=C1CO XMUZQOKACOLCSS-UHFFFAOYSA-N 0.000 description 1
- YIMQCDZDWXUDCA-UHFFFAOYSA-N [4-(hydroxymethyl)cyclohexyl]methanol Chemical compound OCC1CCC(CO)CC1 YIMQCDZDWXUDCA-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- FNGGVJIEWDRLFV-UHFFFAOYSA-N anthracene-1,2-dicarboxylic acid Chemical compound C1=CC=CC2=CC3=C(C(O)=O)C(C(=O)O)=CC=C3C=C21 FNGGVJIEWDRLFV-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- YXVFYQXJAXKLAK-UHFFFAOYSA-N biphenyl-4-ol Chemical group C1=CC(O)=CC=C1C1=CC=CC=C1 YXVFYQXJAXKLAK-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- BSDOQSMQCZQLDV-UHFFFAOYSA-N butan-1-olate;zirconium(4+) Chemical compound [Zr+4].CCCC[O-].CCCC[O-].CCCC[O-].CCCC[O-] BSDOQSMQCZQLDV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- YZFOGXKZTWZVFN-UHFFFAOYSA-N cyclopentane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCCC1 YZFOGXKZTWZVFN-UHFFFAOYSA-N 0.000 description 1
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- VNGOYPQMJFJDLV-UHFFFAOYSA-N dimethyl benzene-1,3-dicarboxylate Chemical compound COC(=O)C1=CC=CC(C(=O)OC)=C1 VNGOYPQMJFJDLV-UHFFFAOYSA-N 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- LHLUQDDQLCJCFU-UHFFFAOYSA-L disodium;1-sulfocyclohexa-3,5-diene-1,3-dicarboxylate Chemical compound [Na+].[Na+].OS(=O)(=O)C1(C([O-])=O)CC(C([O-])=O)=CC=C1 LHLUQDDQLCJCFU-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 239000005003 food packaging material Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000004611 light stabiliser Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- RXOHFPCZGPKIRD-UHFFFAOYSA-N naphthalene-2,6-dicarboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=CC(C(=O)O)=CC=C21 RXOHFPCZGPKIRD-UHFFFAOYSA-N 0.000 description 1
- WPUMVKJOWWJPRK-UHFFFAOYSA-N naphthalene-2,7-dicarboxylic acid Chemical compound C1=CC(C(O)=O)=CC2=CC(C(=O)O)=CC=C21 WPUMVKJOWWJPRK-UHFFFAOYSA-N 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- OTLDLKLSNZMTTA-UHFFFAOYSA-N octahydro-1h-4,7-methanoindene-1,5-diyldimethanol Chemical compound C1C2C3C(CO)CCC3C1C(CO)C2 OTLDLKLSNZMTTA-UHFFFAOYSA-N 0.000 description 1
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- YEBIHIICWDDQOL-YBHNRIQQSA-N polyoxin Polymers O[C@@H]1[C@H](O)[C@@H](C(C=O)N)O[C@H]1N1C(=O)NC(=O)C(C(O)=O)=C1 YEBIHIICWDDQOL-YBHNRIQQSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/66—Polyesters containing oxygen in the form of ether groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
The purpose of the present invention is to provide an antiviral resin composition which can exhibit high antiviral properties by itself without adding additives such as metal oxides, and which can be processed as molded articles into injection molded articles, extrusion molded articles, films, fibers, nonwoven fabrics and foams. The antiviral resin composition of the present invention is characterized by comprising a block copolymer having an antiviral activity value of 2 or more after 24 hours, wherein the block copolymer is a block copolymer comprising an aliphatic polyether.
Description
Technical Field
The present invention relates to an antiviral resin composition and a molded article.
Background
In recent years, since infections caused by various viruses such as novel coronaviruses are life-threatening, countermeasures against them have been eagerly demanded in the world. From such a viewpoint, demand for antiviral materials is increasing, and on the other hand, antiviral properties are demanded for all products.
As such an antiviral material, for example, as in patent document 1, a material in which a metal oxide formed of silver, copper, zinc, or the like is dispersed in a resin has been reported. However, there is a problem in that the metal oxide bleeds out. In addition, there is a problem in that the resin to be mixed is deteriorated by the metal oxide.
On the other hand, as in patent document 2, polyvinyl alcohol having an amino group is reported as a polymer compound exhibiting antiviral properties without adding a metal oxide.
Prior art literature
Patent literature
Patent document 1: japanese patent laid-open publication No. 2018-172462
Patent document 2: international publication No. 2017/171066
Disclosure of Invention
Problems to be solved by the invention
However, it is considered that the polymer compound of patent document 2, i.e., the polyvinyl alcohol having an amino group, has a problem in molding processability, and a new material is demanded.
The purpose of the present invention is to provide an antiviral resin composition which can exhibit high antiviral properties even without adding an additive such as a metal oxide, and which can be processed into injection molded articles, extrusion molded articles, films, fibers, nonwoven fabrics and foams as molded articles.
Means for solving the problems
The present inventors have found that a block copolymer containing an aliphatic polyether has high antiviral properties even without adding an additive such as a metal oxide, and that a resin composition containing the block copolymer exhibits antiviral properties.
Specifically, the present invention provides an antiviral resin composition comprising a block copolymer having an antiviral activity value of 2 or more after 24 hours, wherein the block copolymer is a block copolymer comprising an aliphatic polyether.
ADVANTAGEOUS EFFECTS OF INVENTION
According to the present invention, an antiviral resin composition which is free from exudation of a metal oxide or deterioration due to a metal oxide, and which exhibits high antiviral properties and excellent moldability can be obtained.
Detailed Description
The present invention will be described in detail below.
The antiviral resin composition of the present invention contains a block copolymer having an antiviral activity value of 2 or more after 24 hours. The block copolymer of the present invention has an antiviral activity value of 2 or more after 24 hours in the antiviral property test (SARS-CoV-2) described later. The antiviral resin composition of the present invention has antiviral properties by containing a block copolymer having an antiviral activity value of 2 or more after 24 hours.
In the present invention, "antiviral" means a property of inactivating a pathogenic virus. The antiviral properties were evaluated by the antiviral activity value (Mv) after 24 hours and the viral reduction rate (%) after 24 hours, which will be described later.
The block copolymer of the present invention is a block copolymer comprising an aliphatic polyether. The block copolymer containing an aliphatic polyether can suppress the virus activity by containing an aliphatic polyether. Further, the block copolymer containing an aliphatic polyether is excellent in molding processability.
[ aliphatic polyether ]
Specific examples of aliphatic polyethers include poly (ethylene oxide) glycol, poly (propylene oxide) glycol, poly (oxetane) glycol, poly (tetrahydrofuran) glycol, poly (oxetane) glycol, copolymers of ethylene oxide and propylene oxide, copolymers of cyclopentane and heptane, copolymers of pentane and decane, ethylene oxide adducts of poly (propylene oxide) glycol, and copolymers of ethylene oxide and pentane. Among them, ethylene oxide adducts and/or copolymers of ethylene oxide and oxolane containing poly (tetrahydrofuran) glycol and/or poly (propylene oxide) glycol are preferred. Among them, ethylene oxide adducts containing poly (tetrahydrofuran) glycol and poly (propylene oxide) glycol are preferable. In addition, for example, the poly (propylene oxide) glycol is polypropylene oxide or polypropylene glycol, and the poly (tetrahydrofuran) glycol is poly (tetrahydrofuran) or polytetramethylene ether glycol.
The number average molecular weight of these aliphatic polyethers is preferably 300 to 6000 in a copolymerized state. The number average molecular weight can be determined by general organic analysis.
The copolymerization ratio of the aliphatic polyether including the block copolymer of the aliphatic polyether is more preferably 9% or more, more preferably 20% or more, more preferably 25% or more, more preferably 30% or more, more preferably 35% or more, more preferably 40% or more, more preferably 45% or more, more preferably 50% or more.
The copolymerization ratio of the aliphatic polyether including the block copolymer of the aliphatic polyether is a ratio of the aliphatic polyether unit including the block copolymer of the aliphatic polyether as a diol component. That is, the ratio of the amount of the aliphatic polyether derived from the raw material excluding the water molecule component formed by the ester bond to the amount of the entire block copolymer containing the aliphatic polyether is represented by mass%. The composition of the raw materials can be calculated directly if it is clear. The block copolymer containing the aliphatic polyether can be obtained by structural analysis by NMR.
Examples of the block copolymer containing an aliphatic polyether of the present invention include thermoplastic polyester elastomers, thermoplastic polyamide elastomers, and thermoplastic polyurethane elastomers. Among them, thermoplastic polyester elastomers and thermoplastic polyamide elastomers are preferable, and thermoplastic polyester elastomers are more preferable.
[ thermoplastic polyester elastomer ]
The thermoplastic polyester elastomer used in the present invention is a copolymer of a high-melting crystalline polymer segment and a low-melting polymer segment.
The high-melting crystalline polymer segment is a polyester formed from an aromatic dicarboxylic acid or an ester-forming derivative thereof and a diol or an ester-forming derivative thereof.
Specific examples of the aromatic dicarboxylic acid include terephthalic acid, isophthalic acid, phthalic acid, naphthalene-2, 6-dicarboxylic acid, naphthalene-2, 7-dicarboxylic acid, anthracene dicarboxylic acid, diphenyl-4, 4 '-dicarboxylic acid, diphenoxyethane dicarboxylic acid, 4' -diphenyl ether dicarboxylic acid, 5-sulfoisophthalic acid, and sodium 3-sulfoisophthalate. In the present invention, the above-mentioned aromatic dicarboxylic acid is mainly used, but a part of the aromatic dicarboxylic acid may be replaced with an aliphatic dicarboxylic acid such as an alicyclic dicarboxylic acid, e.g., 1, 4-cyclohexanedicarboxylic acid, cyclopentanedicarboxylic acid, and 4,4' -dicyclohexyldicarboxylic acid, an aliphatic dicarboxylic acid, e.g., adipic acid, succinic acid, oxalic acid, sebacic acid, dodecanedioic acid, and dimer acid. Further, ester-forming derivatives of dicarboxylic acids, such as lower alkyl esters, aryl esters, carbonates, and acid halides, may be equally used.
In the present invention, 2 or more kinds of the above acid components may be used. Examples thereof include combinations of terephthalic acid and isophthalic acid, terephthalic acid and dodecanedioic acid, terephthalic acid and dimer acid, and the like.
The diols to be used in the high-melting crystalline polymer segment are preferably diols having a molecular weight of 400 or less, for example, aliphatic diols such as 1, 4-butanediol, ethylene glycol, 1, 3-propanediol, 1, 5-pentanediol, 1, 6-hexanediol, neopentyl glycol, and 1, 10-decanediol, alicyclic diols such as 1, 1-cyclohexanedimethanol, 1, 4-cyclohexanedimethanol, and tricyclodecanedimethanol, and aromatic diols such as xylylene glycol, bis (p-hydroxy) biphenyl, bis (p-hydroxy) diphenylpropane, 2' -bis [4- (2-hydroxyethoxy) phenyl ] propane, bis [4- (2-hydroxyethoxy) phenyl ] sulfone, 1-bis [4- (2-hydroxyethoxy) phenyl ] cyclohexane, 4' -dihydroxy-p-terphenyl, and 4,4' -dihydroxy-p-tetrabiphenyl, and the like, and these diols may be used in the form of ester forming derivatives such as acetyl and alkali metal salts. These dicarboxylic acids, derivatives thereof, diol components and derivatives thereof may be used in combination of 2 or more.
The low-melting polymer segment is aliphatic polyether, but aliphatic polyester and aliphatic polycarbonate may be used in combination. Specific examples of the aliphatic polyester include poly (. Epsilon. -caprolactone), polyheptalactone, polyoxin lactone, polybutylene adipate, and the like. The aliphatic polycarbonate is preferably composed mainly of an aliphatic diol residue having 2 to 12 carbon atoms. Examples of the aliphatic diols include ethylene glycol, 1, 3-propanediol, 1, 4-butanediol, 1, 5-pentanediol, 1, 6-hexanediol, 1, 8-octanediol, 2-dimethyl-1, 3-propanediol, 3-methyl-1, 5-pentanediol, 2, 4-diethyl-1, 5-pentanediol, 1, 9-nonanediol, and 2-methyl-1, 8-octanediol.
The block copolymer containing an aliphatic polyether of the present invention may contain additives such as antioxidants, ultraviolet absorbers, light stabilizers, antistatic agents, surfactants, lubricants, dyes, pigments, plasticizers, flame retardants, and the like, as required, within a range not impairing the purpose.
The antiviral resin composition of the present invention may be composed of only a block copolymer containing an aliphatic polyether, and may be added with other polymers, additives, talc, mica, glass flakes, calcium carbonate, clay, barium sulfate, glass beads, glass fibers, carbon fibers, cellulose nanofibers, and other reinforcing materials as needed, within a range not detrimental to the purpose.
Specific examples of the virus of the present invention include influenza virus, coronavirus, SARS-CoV-2, hepatitis C virus, japanese encephalitis virus, zika virus, rubella virus, measles virus, human RS virus, rabies virus, crimedean Congo hemorrhagic fever virus, ebola virus, marburg virus, hepatitis D virus, smallpox virus, hepatitis B virus, human immunodeficiency virus, norovirus, feline calicivirus, adenovirus, hepatitis A virus, poliovirus, coxsackie virus, enterovirus, rotavirus, parvovirus, astrovirus, and sabal virus.
The molded article of the present invention is produced by processing the antiviral resin composition of the present invention. Specific forms of the molded article of the present invention are injection molded articles, extrusion molded articles, films, fibers, nonwoven fabrics, foams and the like.
The antiviral resin composition of the present invention is preferably used for an outer layer of an article to which antiviral properties are desired. That is, the method for providing an article having antiviral properties preferably comprises a step of providing an outer layer of the article, the outer layer comprising the antiviral resin composition of the present invention. The outer layer here refers to a surface layer portion of a molded body formed by overlapping 2 or more layers or an exposed surface of a single-layer molded body, and examples thereof include a film layer of an in-mold molded body, a layer of a bicolor molded article contacting a person, and an exposed surface of an uncovered mask.
In addition, the use of the antiviral resin composition of the present invention for imparting an antiviral property to the surface of an article is preferable for the outer layer of the article.
Examples of the use of the antiviral resin composition of the present invention include wallpaper, flooring material, window curtains, clothes, garbage cans, food packaging material, adhesive plaster, mask, bandage, tableware, furniture, toy, bathroom component, toilet component, kitchen component, household electrical appliance, filter (air cleaner), bedding (blanket, bedding, bed sheet), seat (car seat, train seat, aircraft seat, chair seat for home use), handrail belt, handrail, sponge (cleaning, dishwashing, filter material), diaper, cleaning tool, material for preventing contamination diffusion, and material for automobile interior.
Examples
The effects of the present invention are described below by way of examples. In addition, the% and parts in the examples are all weight basis unless otherwise indicated. The physical properties shown in examples were measured as follows.
[ thermoplastic polyester elastomer (A-1) ]
270.0 parts of terephthalic acid, 234.0 parts of 1, 4-butanediol and 0.1 part of tetrabutyl titanate and 0.1 part of mono-n-butyl-monohydroxy tin oxide were charged into an esterification tank having a rectifying tower and a stirrer, and the esterification reaction was started under a reduced pressure of 700mmHg at 160 ℃. Then, the temperature was gradually raised, and 59.0 parts of 1, 4-butanediol was further added continuously. After 3 hours and 40 minutes from the start of the reaction, a transparent reaction product was obtained, and the reaction was terminated. After completion of the esterification reaction, 1.8 parts of tetrabutyl titanate as a polycondensation catalyst and 1.0 parts of "IRGANOX"1330 (manufactured by BASF corporation) as a stabilizer were added to the esterification tank, while 686.0 parts of poly (tetrahydrofuran) diol having a number average molecular weight of 1400 was added to the polycondensation tank, and the esterification reaction product was transferred from the esterification tank to the polycondensation tank. Further, while stirring polymerization of the reaction system in the polycondensation tank, a reduced pressure system was gradually formed over 1 hour from normal pressure to a high vacuum of 1mmHg or less, and the temperature was raised to 245℃and polycondensation was carried out under the conditions of 245℃and 1mmHg or less for 3 hours and 30 minutes, whereby a thermoplastic polyester elastomer (A-1) having a copolymerization ratio of an aliphatic polyether component of 68% was obtained.
[ thermoplastic polyester elastomer (A-2) ]
501.0 parts of terephthalic acid, 326.0 parts of 1, 4-butanediol and 0.3 part of tetrabutyl titanate, and 0.2 part of mono-n-butyl-monohydroxy tin oxide were charged into an esterification tank having a rectifying column and a stirrer, and esterification was started under reduced pressure of 650mmHg at 160 ℃. Then, the temperature was gradually raised, and 81.0 parts of 1, 4-butanediol was further added continuously, while changing the pressure reduction degree from the middle of the reaction to 500mmHg. After 3 hours and 40 minutes from the start of the reaction, a transparent reaction product was obtained, and the reaction was terminated. After completion of the esterification reaction, 2.0 parts of tetrabutyl titanate as a polycondensation catalyst and 0.5 parts of "IRGANOX"1098 (manufactured by BASF corporation) as a stabilizer were added to the esterification tank, while 354.0 parts of poly (tetrahydrofuran) diol having a number average molecular weight of 1400 was added to the polycondensation tank, and the esterification reaction product was transferred from the esterification tank to the polycondensation tank. Further, while stirring polymerization of the reaction system in the polycondensation tank, a reduced pressure system was gradually formed over 1 hour from normal pressure to a high vacuum of 1mmHg or less, and the temperature was raised to 245℃and polycondensation was carried out at 245℃for 3 hours and 30 minutes under 1mmHg or less, whereby a thermoplastic polyester elastomer (A-2) having a copolymerization ratio of an aliphatic polyether component of 35% was obtained.
[ thermoplastic polyester elastomer (A-3) ]
591.0 parts of terephthalic acid, 385.0 parts of 1, 4-butanediol and 0.3 parts of tetrabutyl titanate and 0.1 part of mono-n-butyl-monohydroxy tin oxide were charged into an esterification tank having a rectifying column and a stirrer, and the esterification reaction was started under a reduced pressure of 500mmHg at 160 ℃. Then, the temperature was gradually raised, and 96.0 parts of 1, 4-butanediol was further added continuously. After 3 hours and 40 minutes from the start of the reaction, a transparent reaction product was obtained, and the reaction was terminated. After completion of the esterification reaction, 1.5 parts of tetrabutyl titanate as a polycondensation catalyst and 0.5 parts of "IRGANOX"1098 (manufactured by BASF corporation) as a stabilizer were added to the esterification tank, and 231.0 parts of poly (tetrahydrofuran) diol having a number average molecular weight of 1400 was added to the polycondensation tank, and then the esterification reaction product was transferred from the esterification tank to the polycondensation tank. Further, while stirring polymerization of the reaction system in the polycondensation tank, a reduced pressure system was gradually formed over 1 hour from normal pressure to a high vacuum of 1mmHg or less, and the temperature was raised to 245℃and polycondensation was carried out at 245℃and 1mmHg or less for 3 hours and 30 minutes, whereby a thermoplastic polyester elastomer (A-3) having a copolymerization ratio of the aliphatic polyether component of 23% was obtained.
[ thermoplastic polyester elastomer (A-4) ]
340.0 parts of terephthalic acid, 100 parts of isophthalic acid, 296.0 parts of 1, 4-butanediol and 0.3 part of tetrabutyl titanate and 0.1 part of mono-n-butyl-monohydroxy tin oxide were charged into an esterification tank having a rectifying tower and a stirrer, and the esterification reaction was started under a reduced pressure of 500mmHg at 160 ℃. Then, the temperature was gradually raised, and 74.0 parts of 1, 4-butanediol was further added continuously. After 3 hours and 40 minutes from the start of the reaction, a transparent reaction product was obtained, and the reaction was terminated. After completion of the esterification reaction, 1.9 parts of tetrabutyl titanate as a polycondensation catalyst and 0.5 parts of "IRGANOX"1098 (manufactured by BASF corporation) as a stabilizer were added to the esterification tank, while 495.0 parts of poly (tetrahydrofuran) diol having a number average molecular weight of 1400 was added to the polycondensation tank, and the esterification reaction product was transferred from the esterification tank to the polycondensation tank. Further, while stirring polymerization of the reaction system in the polycondensation tank, a reduced pressure system was gradually formed over 1 hour from normal pressure to a high vacuum of 1mmHg or less, and the temperature was raised to 245℃and polycondensation was carried out at 245℃for 3 hours and 30 minutes under 1mmHg or less, whereby a thermoplastic polyester elastomer (A-4) having a copolymerization ratio of an aliphatic polyether component of 47% was obtained.
[ thermoplastic polyester elastomer (A-5) ]
312 parts of dimethyl terephthalate and 91 parts of dimethyl isophthalate, which are high-melting crystalline polymer segments formed from a crystalline aromatic polyester, 537 parts of an ethylene oxide adduct of poly (propylene oxide) glycol, which is a low-melting polymer segment formed from an aliphatic polyether unit and has a number average molecular weight of 2150, 167 parts of 1, 4-butanediol, and 4 parts of titanium tetrabutoxide, were charged into a reaction vessel equipped with a ribbon-type stirring blade, and methanol was distilled out of the system by heating at 190 to 225 ℃ for 3 hours. After 2 parts of each of "IRGANOX"1098 and 1019 (manufactured by BASF corporation) was added to the reaction mixture, the temperature was raised to 243℃and then the pressure in the system was reduced to 0.2mmHg over 50 minutes, and polymerization was carried out under these conditions for 3 hours, whereby a thermoplastic polyester elastomer (A-5) having a copolymerization ratio of an aliphatic polyether component of 55% was obtained.
[ thermoplastic polyester elastomer (A-6) ]
501.0 parts of terephthalic acid, 326.0 parts of 1, 4-butanediol and 0.3 part of tetrabutyl titanate, and 0.2 part of mono-n-butyl-monohydroxy tin oxide were charged into an esterification tank having a rectifying column and a stirrer, and esterification was started under reduced pressure of 650mmHg at 160 ℃. Then, the temperature was gradually raised, and 81.0 parts of 1, 4-butanediol was further added continuously, while changing the pressure reduction degree from the middle of the reaction to 500mmHg. After 3 hours and 40 minutes from the start of the reaction, a transparent reaction product was obtained, and the reaction was terminated. After completion of the esterification reaction, 2.0 parts of tetrabutyl titanate as a polycondensation catalyst and 0.5 parts of "IRGANOX"1098 (manufactured by BASF corporation) as a stabilizer were added to the esterification tank, while 354.0 parts of a copolymer of oxolane and oxodecane having a number average molecular weight of 1400 was added to the polycondensation tank, and the esterification reaction product was transferred from the esterification tank to the polycondensation tank. Further, while stirring polymerization of the reaction system in the polycondensation tank, a reduced pressure system was gradually formed over 1 hour from normal pressure to a high vacuum of 1mmHg or less, and the temperature was raised to 245℃and polycondensation was carried out at 245℃for 3 hours and 30 minutes under 1mmHg or less, whereby a thermoplastic polyester elastomer (A-6) having a copolymerization ratio of an aliphatic polyether component of 35% was obtained.
[ thermoplastic polyester elastomer (A-7) ]
700.0 parts of terephthalic acid, 759.0 parts of 1, 4-butanediol and 0.3 parts of tetrabutyl titanate and 0.1 parts of mono-n-butyl-monohydroxy tin oxide were charged into an esterification tank having a rectifying tower and a stirrer, and an esterification reaction was started under a reduced pressure of 500mmHg at 160 ℃. After 3 hours and 40 minutes from the start of the reaction, a transparent reaction product was obtained, and the reaction was terminated. After completion of the esterification reaction, 1.5 parts of tetrabutyl titanate as a polycondensation catalyst and 0.5 parts of "IRGANOX"1330 (manufactured by BASF corporation) as a stabilizer were added to the esterification tank, while 80.0 parts of poly (tetrahydrofuran) diol having a number average molecular weight of 1000 was added to the polycondensation tank, and the esterification reaction product was transferred from the esterification tank to the polycondensation tank. Further, while stirring polymerization of the reaction system in the polycondensation tank, a reduced pressure system was gradually formed over 1 hour from normal pressure to a high vacuum of 1mmHg or less, and the temperature was raised to 245℃and polycondensation was carried out at 245℃and 1mmHg or less for 3 hours and 30 minutes, whereby a thermoplastic polyester elastomer (A-7) having a copolymerization ratio of an aliphatic polyether component of 8% was obtained.
[ PBT resin (B) ]
トレコン TM 1100S (manufactured by Tong Yue Co., ltd.). Polymers of terephthalic acid with 1, 4-butanediol.
[ thermoplastic Polyamide elastomer (C) ]
Into the pressure vessel were charged 98.00 parts of 12-aminododecanoic acid and 7.66 parts of adipic acid. After the nitrogen substitution, the mixture was slowly heated while nitrogen was supplied, and polymerized at 230℃for 4 hours to synthesize an oligomer of nylon 12. To this oligomer were added 642.5 parts of poly (tetrahydrofuran) diol having a number average molecular weight of 1800, 0.20 part of tetrabutyl zirconate, and 0.50 part of antioxidant "IRGANOX"1098 (manufactured by BASF). After the nitrogen substitution, the thermoplastic polyamide elastomer (C) was obtained by heating the thermoplastic polyamide elastomer slowly while supplying nitrogen thereto, heating the thermoplastic polyamide elastomer at 210℃for 3 hours, then slowly depressurizing the thermoplastic polyamide elastomer, changing the temperature to 50Pa over 1 hour, polymerizing the thermoplastic polyamide elastomer for 2 hours, further heating and depressurizing the thermoplastic polyamide elastomer for 30 minutes, and polymerizing the thermoplastic polyamide elastomer for 3 hours at 230℃and 30Pa, wherein the copolymerization ratio of the aliphatic polyether component is 81%.
[ Molding of test piece ]
A square test piece of 80X 1mm was obtained from the pellets by injection molding using an injection molding machine NEX-1000 manufactured by Nikkin resin industries, ltd. Since injection molding is possible, it can be processed into injection molded articles, extrusion molded articles, films, fibers, nonwoven fabrics and foams.
[ antiviral test (SARS-CoV-2) ]
Determination of antiviral Activity essentially follows JISZ2801:2012 antimicrobial fabricated articles were subjected to an antimicrobial test.
The virus used was SARS-CoV-2/JP/Hiroshima-46059T/2020 strain (Pango Linear: B.1.1), and VeroE6/TMPRSS2 cells (JCRB 1819: purchased from JCRB cell bank) were used as culture cells. The experiments were performed in the university of Tsingtao university medical science research department P3 experimental facility. Viruses can also be assessed by other viruses belonging to the species SARS-CoV-2.
The test piece was cut into 5cm square pieces, immersed in 80% ethanol for 5 seconds to sterilize, and then dried in a safe cabinet while blowing sterile air through a HEPA filter. Mu.l of the virus solution was dropped onto the test piece, and Parafilm (4 cm square) subjected to ethanol sterilization was covered from above to spread the virus solution uniformly. The virus solution was collected after being placed in a wet box at 23℃and allowed to react at room temperature for 0 or 24 hours. The 0 hour is when virus is recovered within 1 minute after the virus solution is dropped onto the test piece.
The reacted virus liquid was serially diluted 10 times with DMEM to obtain 10 -1 ～10 -8 Multiple dilutions. 50. Mu.l of each dilution was plated on 4-well cells in a 96-well plate, and after 1 hour of adsorption, the plating was exchanged for 100. Mu.l/well DMEM. Infection was determined after 3 days using the appearance of the cell degeneration effect as an index, and 50% of the tissue culture infection amount (TCID) was calculated using the Behrens-Kraber algorithm 50 ) Each ml was defined as the infectious titer of the virus.
[ antiviral Property test (FCV) ]
Determination of antiviral Activity essentially follows JISZ2801:2012 antimicrobial fabricated articles were subjected to an antimicrobial test.
The Feline Calicivirus (FCV) F9 strain (ATCC VR-782) was used as the virus, and CRFK cells (ATCC CCL-94) were used as the cultured cells. Experiments were performed in the university of Tsingtao university medical science research department P2 experimental facility.
The test piece was cut into 5cm squares, and sterilized by irradiation with ultraviolet rays for 30 minutes in a safety cabinet. Mu.l of the virus solution was dropped onto the test piece, and Parafilm (4 cm square) subjected to ethanol sterilization was covered from above, and the virus solution was spread uniformly. The virus solution was collected after being placed in a wet box at 23℃and allowed to react at room temperature for 0 or 24 hours. The 0 hour is when virus is recovered within 1 minute after the virus solution is dropped onto the test piece.
The reacted virus liquid was serially diluted 10 times with DMEM to obtain 10 -1 ～10 -8 Multiple dilutions. 50. Mu.l of each dilution was inoculated into 4-well cells in a 96-well plate, and after 1 hour of adsorption, the inoculum was exchanged for 100. Mu.l/well DMEM. After 5 days, infection was determined by using the appearance of the cell degeneration effect as an index, and 50% of the tissue culture infection amount (TCID) was calculated by using the Behrens-Kraber algorithm 50 ) Each ml was defined as the infectious titer of the virus.
[ antiviral test (influenza Virus) ]
The antiviral activity was measured according to ISO21702 (2019).
The virus used was influenza virus (INFLUENZA A VIRUS (H3N 2): ATCC VR-1679). Experiments were performed in general financial groups favicon. The test liquid intake was 0.4mL, and SCDLP medium was used as the eluate. The term "0 hour" means that the virus solution is recovered immediately after inoculation.
[ antiviral Activity value ]
The virus infection titer after 0 hour was defined as Vb, the virus infection titer after 24 hours was defined as Vc, and the antiviral activity value (Mv) after 24 hours and the virus reduction rate (%) after 24 hours were determined by the following formulas.
Antiviral activity value (Mv) =lg10 (Vb) -lg10 (Vc) after 24 hours
Viral reduction (%) = [ (Vb-Vc) ×100]/Vb after 24 hours.
Example 1
The thermoplastic polyester elastomer (A-1) was used for evaluation.
Example 2
The thermoplastic polyester elastomer (A-1) was used, and the virus type of example 1 was changed, and evaluated.
Example 3
The thermoplastic polyester elastomer (A-1) was used, and the virus type of example 1 was changed, and evaluated.
Example 4
The thermoplastic polyester elastomer (A-2) was used for evaluation.
Example 5
The thermoplastic polyester elastomer (A-3) was used for evaluation.
Example 6
The thermoplastic polyester elastomer (A-4) was used for evaluation.
Example 7
The thermoplastic polyester elastomer (A-5) was used for evaluation.
Example 8
The thermoplastic polyester elastomer (A-6) was used for evaluation.
Example 9
The thermoplastic polyamide elastomer (C) was used for evaluation.
Comparative example 1
The PBT resin (B) was used for evaluation.
Comparative example 2
The thermoplastic polyester elastomer (A-7) was used for evaluation.
Comparative example 3
The PBT resin (B) was used to change the virus type of comparative example 1, and the evaluation was performed.
Tables 1 and 2 show the materials of examples and comparative examples, the ratio of aliphatic polyether components, the virus infection titer at 0 hours and 24 hours, the antiviral activity value after 24 hours, and the virus reduction rate after 24 hours.
As is clear from examples 1 to 9, the thermoplastic polyester elastomers (A-1), (A-2), (A-3), (A-4), (A-5), (A-6) and the thermoplastic polyamide elastomer (C) containing the aliphatic polyether component have a large effect of reducing viruses.
Further, as is clear from comparative examples 1, 2 and 3, the effect of reducing viruses was small for the PBT resin (B) and the thermoplastic polyester elastomer (A-7) which did not contain the aliphatic polyether component or contained a small amount.
TABLE 1
TABLE 2
Claims (5)
1. An antiviral resin composition comprising a block copolymer having an antiviral activity value of 2 or more after 24 hours, wherein the block copolymer comprises an aliphatic polyether.
2. The antiviral resin composition according to claim 1, wherein the block copolymer containing an aliphatic polyether is a thermoplastic polyester elastomer.
3. The antiviral resin composition according to claim 1 or 2, wherein the copolymerization ratio of the aliphatic polyether comprising the block copolymer of aliphatic polyether is 9% or more.
4. The antiviral resin composition according to any one of claims 1 to 3, wherein the aliphatic polyether is a poly (tetrahydrofuran) glycol or an ethylene oxide adduct of a poly (propylene oxide) glycol.
5. A molded article obtained by processing the antiviral resin composition according to any one of claims 1 to 4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-008575 | 2021-01-22 | ||
| JP2021008575 | 2021-01-22 | ||
| PCT/JP2022/001323 WO2022158411A1 (en) | 2021-01-22 | 2022-01-17 | Antiviral resin composition and molded body |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116848174A true CN116848174A (en) | 2023-10-03 |
Family
ID=82549715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280009992.7A Pending CN116848174A (en) | 2021-01-22 | 2022-01-17 | Antiviral resin composition and molded article |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP7183477B1 (en) |
| CN (1) | CN116848174A (en) |
| TW (1) | TW202239810A (en) |
| WO (1) | WO2022158411A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024010084A1 (en) * | 2022-07-08 | 2024-01-11 | 東レ・セラニーズ株式会社 | Resin composition for outer layer of antibacterial article, molded body, and antibacterial article |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10221177A (en) * | 1997-02-07 | 1998-08-21 | Terumo Corp | Electronic clinic thermomerer |
| JP4665393B2 (en) * | 2002-11-28 | 2011-04-06 | 東レ・デュポン株式会社 | Thermoplastic elastomer resin composition and molded body |
| JP4106655B2 (en) * | 2003-05-27 | 2008-06-25 | 宇部興産株式会社 | Plasticizer-containing resin composition and molded product |
| DE10361190A1 (en) * | 2003-12-24 | 2005-07-28 | Ticona Gmbh | Composite body, process for its preparation and its use |
| JP6874257B2 (en) * | 2016-03-09 | 2021-05-19 | 東レ・デュポン株式会社 | Heat-resistant thermoplastic elastomer resin composition |
| JP7129236B2 (en) * | 2017-06-21 | 2022-09-01 | 東レ・デュポン株式会社 | Thermoplastic elastomer resin and its molding |
| JP2019048781A (en) * | 2017-09-11 | 2019-03-28 | 日本ゼオン株式会社 | Antibacterial agent, composition for molded body and crosslinking composition using the same |
| JP2021066794A (en) * | 2019-10-23 | 2021-04-30 | 東レ株式会社 | Polymer composition having amide bond for molding subjected to high-pressure hydrogen, and molding including the same |
-
2022
- 2022-01-17 JP JP2022510926A patent/JP7183477B1/en active Active
- 2022-01-17 WO PCT/JP2022/001323 patent/WO2022158411A1/en active Application Filing
- 2022-01-17 CN CN202280009992.7A patent/CN116848174A/en active Pending
- 2022-01-21 TW TW111102553A patent/TW202239810A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022158411A1 (en) | 2022-07-28 |
| TW202239810A (en) | 2022-10-16 |
| JP7183477B1 (en) | 2022-12-05 |
| WO2022158411A1 (en) | 2022-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110021697A1 (en) | Methods for preparing polyether ester elastomer composition | |
| US7582690B2 (en) | Stabilized aliphatic polyester compositions | |
| JP5139982B2 (en) | Polylactic acid-based resin composition, molded article thereof, and polylactic acid-based compound | |
| MXPA94003135A (en) | The use of a textile lamination plastic being provided with a copolyether-ester film for the production of water-proof clothes, shoes, tents and covers. | |
| CN116848174A (en) | Antiviral resin composition and molded article | |
| EP2256144B1 (en) | Polylactic acid resin, polylactic acid resin composition, molded body of polylactic acid resin or polylactic acid resin composition, and method for producing polylactic acid resin | |
| JP2006161017A (en) | Novel polyoxalate | |
| JP2015120838A (en) | Porous sheet | |
| US9624341B2 (en) | Glycolide-based polyesters | |
| TWI297698B (en) | Resin for molding and production method thereof | |
| CN116917410A (en) | Antiviral resin composition containing hydrophilic polymer and molded body | |
| US9394402B2 (en) | Glycolide-based polyesters made with isosorbide | |
| KR101374367B1 (en) | Radiation resistant resin and medical housings using the same | |
| WO2006083044A1 (en) | Lactic acid/oxalate block copolymer | |
| JP2005060686A (en) | Polylactic acid composition and shaped article obtained from the same | |
| WO2024010084A1 (en) | Resin composition for outer layer of antibacterial article, molded body, and antibacterial article | |
| de Ilarduya et al. | Polyesters Based on Cyclohexanedimethanol | |
| JP2005097590A (en) | Polyoxalate composition and molded product obtained therefrom | |
| JP4089575B2 (en) | Cellulose ester composition and molded product obtained therefrom | |
| JP4089579B2 (en) | Wooden resin composition | |
| US20230340189A1 (en) | Polyester | |
| JP2006290937A (en) | Cellulosic waste-polyoxalate composite | |
| KR20190050162A (en) | Sheath-core type polyester composite fiber having improved Flexibility and fabric comprising the same | |
| JPH0684427B2 (en) | Method for producing copolyester molding | |
| KR20190065721A (en) | Hydrophilic Polyester resin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |